# Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease

> **NIH NIH R01** · VIROGENICS, INC. · 2022 · $210,130

## Abstract

Abstract
 The parent grant for this application supports a Phase I clinical trial of CMS121, a small molecule that
has shown efficacy in multiple mouse models of Alzheimer's Disease and which affords a different
therapeutic approach for treatment of AD in humans. In this application we request supplemental funds to
cover the costs of COVID-19 mitigation procedures and COVID-19 testing of trial subjects. These
processes and associated costs were not necessary at the time of application due in large part to the
rollout of highly effective vaccines and declining infections but have become essential now due to repeated
surges in infections and the appearance of highly infectious variants of the virus. The mitigation and
testing procedures are necessary to protect the clinical and non-clinical staff, as well as trial subjects at the
clinical site from COVID-19 infection.

## Key facts

- **NIH application ID:** 10542565
- **Project number:** 3R01AG074447-01S1
- **Recipient organization:** VIROGENICS, INC.
- **Principal Investigator:** Pamela Anne Maher
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $210,130
- **Award type:** 3
- **Project period:** 2021-09-15 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10542565

## Citation

> US National Institutes of Health, RePORTER application 10542565, Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease (3R01AG074447-01S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10542565. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*